MedTrace Logo

Study of Telaprevir in Subjects With Hepatic Impairment

NCT00509210 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2008-10-29

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.

Conditions

  • Hepatic Insufficiency

Interventions

DRUG

telaprevir (VX-950)

Sponsors & Collaborators

Principal Investigators

  • Paul Y Kwo, MD · Indiana University, Department of Medicine, Division of Gastroenterology/Hepatology

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00509210 on ClinicalTrials.gov